Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases

Neeraj Mishra; Sumel Ashique; Ashish Garg; Vineet Kumar Rai; Kamal Dua; Amit Goyal; Shvetank Bhatt

doi:10.1016/j.drudis.2022.01.003

Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases

Neeraj Mishra
, Sumel Ashique
, Ashish Garg
, Vineet Kumar Rai
, Kamal Dua
, Amit Goyal
, Shvetank Bhatt

Amity University, Madhya Pradesh
School of Pharmacy
Rani Durgavati Vishwavidyalaya
Punjab Technical University
University of Technology Sydney
Central University of Rajasthan

Research output: Contribution to journal › Review article › peer-review

40 Scopus citations

Abstract

Neurodegenerative disorders (NDs) lead to the progressive degeneration of the structural and physiological functions of the central and peripheral nervous systems, resulting in lifelong cognitive and motor dysfunction. Although comprehensive treatment of NDs is lacking, small interfering (si)RNA has shown therapeutic utility in the form of cellular nuclease-driven downregulation of mRNA levels. Various nanotechnologies have been used to modulate crucial physicochemical and biopharmaceutical properties of siRNA to provide protection and to enhance biomembrane interactions, residence times, tissue absorption, and cellular internalization for improved cytoplasm and/or nucleus interactions. In this review, we highlight advances in, and the role of, siRNA-based nanocarriers for the treatment of various NDs.

Original language	English
Pages (from-to)	1431-1440
Number of pages	10
Journal	Drug Discovery Today
Volume	27
Issue number	5
DOIs	https://doi.org/10.1016/j.drudis.2022.01.003
State	Published - May 2022
Externally published	Yes

Keywords

Liposomes
Nanoparticles
Nanostructured lipid carriers
Neurodegenerative disorders
Small interfering RNA
Solid lipid nanoparticle

Access to Document

10.1016/j.drudis.2022.01.003

Cite this

@article{013e55f48cc14e1aa13d9ed77e354239,

title = "Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases",

abstract = "Neurodegenerative disorders (NDs) lead to the progressive degeneration of the structural and physiological functions of the central and peripheral nervous systems, resulting in lifelong cognitive and motor dysfunction. Although comprehensive treatment of NDs is lacking, small interfering (si)RNA has shown therapeutic utility in the form of cellular nuclease-driven downregulation of mRNA levels. Various nanotechnologies have been used to modulate crucial physicochemical and biopharmaceutical properties of siRNA to provide protection and to enhance biomembrane interactions, residence times, tissue absorption, and cellular internalization for improved cytoplasm and/or nucleus interactions. In this review, we highlight advances in, and the role of, siRNA-based nanocarriers for the treatment of various NDs.",

keywords = "Liposomes, Nanoparticles, Nanostructured lipid carriers, Neurodegenerative disorders, Small interfering RNA, Solid lipid nanoparticle",

author = "Neeraj Mishra and Sumel Ashique and Ashish Garg and Rai, \{Vineet Kumar\} and Kamal Dua and Amit Goyal and Shvetank Bhatt",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = may,

doi = "10.1016/j.drudis.2022.01.003",

language = "English",

volume = "27",

pages = "1431--1440",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "5",

}

TY - JOUR

T1 - Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases

AU - Mishra, Neeraj

AU - Ashique, Sumel

AU - Garg, Ashish

AU - Rai, Vineet Kumar

AU - Dua, Kamal

AU - Goyal, Amit

AU - Bhatt, Shvetank

PY - 2022/5

Y1 - 2022/5

N2 - Neurodegenerative disorders (NDs) lead to the progressive degeneration of the structural and physiological functions of the central and peripheral nervous systems, resulting in lifelong cognitive and motor dysfunction. Although comprehensive treatment of NDs is lacking, small interfering (si)RNA has shown therapeutic utility in the form of cellular nuclease-driven downregulation of mRNA levels. Various nanotechnologies have been used to modulate crucial physicochemical and biopharmaceutical properties of siRNA to provide protection and to enhance biomembrane interactions, residence times, tissue absorption, and cellular internalization for improved cytoplasm and/or nucleus interactions. In this review, we highlight advances in, and the role of, siRNA-based nanocarriers for the treatment of various NDs.

AB - Neurodegenerative disorders (NDs) lead to the progressive degeneration of the structural and physiological functions of the central and peripheral nervous systems, resulting in lifelong cognitive and motor dysfunction. Although comprehensive treatment of NDs is lacking, small interfering (si)RNA has shown therapeutic utility in the form of cellular nuclease-driven downregulation of mRNA levels. Various nanotechnologies have been used to modulate crucial physicochemical and biopharmaceutical properties of siRNA to provide protection and to enhance biomembrane interactions, residence times, tissue absorption, and cellular internalization for improved cytoplasm and/or nucleus interactions. In this review, we highlight advances in, and the role of, siRNA-based nanocarriers for the treatment of various NDs.

KW - Liposomes

KW - Nanoparticles

KW - Nanostructured lipid carriers

KW - Neurodegenerative disorders

KW - Small interfering RNA

KW - Solid lipid nanoparticle

UR - https://www.scopus.com/pages/publications/85123062573

U2 - 10.1016/j.drudis.2022.01.003

DO - 10.1016/j.drudis.2022.01.003

M3 - Review article

C2 - 35017085

AN - SCOPUS:85123062573

SN - 1359-6446

VL - 27

SP - 1431

EP - 1440

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 5

ER -

Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this